Cardinal Health, Inc. (CAH) is a Consumer Discretionary stock trading at $248.54 (as of 2026-09-03), with a market capitalization of $57.81B and a trailing P/E of 34.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Cardinal Health moves drugs, medical supplies, and specialty products to hospitals, pharmacies, and clinics across the U.S. and abroad, earning a thin distribution spread on enormous volume. About 85% of the $65.6 billion quarterly revenue flows through the pharmaceutical segment, where pricing is set by government reimbursement rules rather than by the company itself.
Profit here is a function of volume velocity on a 3.7% gross margin: the company trades working capital, logistics scale, and regulatory relationships for a razor-thin percentage-point spread on $65 billion of quarterly product flow.
| Pharmaceutical | $56.1B |
| Medical | $3.7B |
| Global Medical Products | $3.3B |
| Other | $2.5B |
Business quality (Solid): Solid: dominant U.S. pharma-distribution position with sticky hospital and pharmacy relationships, though structural thinness in margins (1.1% operating) means earnings quality depends heavily on volume growth and cost discipline.
Valuation: At 33× earnings, CAH trades 38% above the Wholesale average (24×).
| Price | $248.54 |
| Market Cap | $57.81B |
| P/E Ratio | 34.8 |
| EV / EBITDA | 15.2 |
| Price / Sales | 0.24 |
| FCF Yield | 7.8% |
| DCF Value (model) | $397.57 |
| DCF Upside vs Price | 60.0% |
| Revenue (TTM) | $254.25B |
| Net Margin | 0.7% |
| Revenue Growth (YoY) | 14.2% |
| EPS Growth (YoY) | 12.2% |
| FCF Growth (YoY) | 144.6% |
| Altman Z-Score | 5.11 (safe) |
| Stock P/E | 34.8 |
| Sector P/E (Consumer Discretionary) | 20.2 |
| Industry P/E (Wholesale) | 23.9 |
| vs Sector | 72.5% |
| vs Industry | 45.8% |
| Top Institutional Holder | VANGUARD GROUP INC ($6.46B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Consumer Discretionary |
| Industry | Wholesale |
| CEO | Jason Hollar |
| Employees | 47,922 |
| Country | US |
| IPO Date | 1983-08-04 |
Data as of 2026-09-03.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.